Cognitive Function and Fatigue in Stable Multiple Sclerosis: EDSS and MRI Assessments Surpass Serum Biomarkers

• by Deborah K. Erhart, Luisa T. Balz, Roland Opfer, Lothar Spies, Franziska Bachhuber, Ioannis Vardakas, Daniela Taranu, Stefanie Jung, Tanja Fangerau, Makbule Senel, Kornelia Kreiser, Ingo Uttner, Dorothée Lulé, Hayrettin Tumani

• April 17, 2026

Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments

• by Francesco Pastore, Emanuela Domenicone, Patrizia DellOro, Charlotte Lefort

• April 20, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

• by Kerri Miller

• April 17, 2026

• 6 min

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

• by Kathryn Wighton

• July 7, 2026

• 6 min